Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
about
Intraocular Implants for the Treatment of Autoimmune UveitisAnti-TNF therapy for juvenile idiopathic arthritis-related uveitisWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?The Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisProfile of adalimumab and its potential in the treatment of uveitisTreatment of Juvenile Idiopathic Arthritis-Associated UveitisUveitis in juvenile idiopathic arthritisEfficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case seriesResponse of pediatric uveitis to tumor necrosis factor-α inhibitors.The development and assessment of biological treatments for children.Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Current perspectives on ophthalmic manifestations of childhood rheumatic diseasesUveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Adalimumab for Ocular Inflammation.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Pediatric uveitis: new and future treatments.Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.Emerging drugs for the treatment of uveitis.Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors.Adalimumab in the treatment of immune-mediated diseases.Treatment of uveitis associated with juvenile idiopathic arthritis.Management of pediatric uveitis.Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.The Use of Biologic Therapies in Uveitis.Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus.Treatment Options for Juvenile Idiopathic Arthritis (JIA) Associated Uveitis.Current Treatment Modalities of JIA-associated Uveitis and its Complications: Literature Review.Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis.Biologics in juvenile idiopathic arthritis: a narrative review.Chronic Non-infectious Uveitis in Patients with Juvenile Idiopathic Arthritis.Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.Adalimumab for the treatment of refractory noninfectious paediatric uveitis.[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications.Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
P2860
Q26799168-09DFE6BE-41E8-4FA0-8D11-48FBE8BBA228Q26849811-BC24D636-1D1E-4ED7-ACA0-240A7BBF8313Q26995394-D6FBE86F-CE3C-417F-891A-B67C678C7C1DQ27025862-D8948040-6038-4451-9385-96F49824B790Q28077781-96FDCF71-DE69-489B-81E1-5098D9CFC29CQ28080084-0395AB5E-175D-42A9-AFF1-D6D548457575Q28086972-6A852881-831D-4006-9A13-FC3F54F5B1B1Q33712570-213118C3-05D1-49E0-9046-38072B294C37Q34789195-69FEEE11-2588-4A44-9428-DFBA2C2F6265Q35135936-298B34F2-B6B8-42A8-A326-CD52F47BDFE6Q36584169-64F3CC9B-05B4-4625-A1EC-E8B91661EBD9Q37007652-C3AA30D9-F00F-4EE5-BB75-CC6B4F688157Q37095406-7ECEC3A4-2726-475D-B56B-CDF9ED2CC20DQ37105146-9155FC5A-C254-4CE8-82C5-D091714A5C19Q37276953-26A8C270-9AF2-4F04-A27D-BC484B5DE73DQ38092899-BD5601FE-678B-4568-964A-C82D5444013AQ38123032-6C0F2A6C-5C1F-4658-8D84-D68B778B8AFAQ38144094-19BF0756-9AA9-4664-8E9E-E93C0023A24FQ38166016-7CCB9B5C-09A5-4FF7-9F82-1BBA0A276DCCQ38172584-A79E035C-EC2E-4FD1-B8DB-451D873D3715Q38207760-3CD3AE90-2670-4039-B8BD-0897CAAC8F3BQ38221012-3409AF2B-E03D-468F-A5A2-30A5AD8CA260Q38225872-9AC11FEC-BC07-48A0-8375-BE8DBD969F24Q38235720-4AE1DD75-3308-47D3-A7B6-956113A4D862Q38250103-2E6CE637-F552-44A8-98D9-E9237AB99B01Q38272248-6ACA0B84-90AB-4E38-B13A-D9C2AA961326Q38345902-2F744E17-4E42-4F1C-8EDA-CF675AF5B947Q38664517-1C82ABDD-0C40-4E4D-99D7-FFA49D35F224Q38696180-12288D4E-88AA-4BCB-BE00-F74A3EEFCFD5Q38711172-3BB78132-D6F0-4042-8CE4-FD082AA740D2Q39336335-62A63529-2430-4607-8174-AD8934BFEC85Q39446782-4E3DBF76-8ED8-4538-AEE7-638681C560B0Q40781984-6000D472-BAC8-4256-93D4-39DC93AEA359Q40919640-1957DB4B-5300-4F12-B33D-099919963449Q41994612-9212F0E1-980D-479C-9C72-2245F50ECD18Q47226473-229AAE2F-8C36-47B8-8DA3-1BA3CB8E0433Q48554997-320CBD4D-6C89-4BAA-939F-835DEA888601Q52852647-EB173880-4163-45DF-8DD1-645E2C349DFDQ54453680-2CE0411D-B37B-46FC-8823-8F4B809CF48DQ57171464-846DACF8-8E6A-4EB4-B48E-5B63262B0E57
P2860
Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Safety and efficacy of inflixi ...... ata from the Italian Registry.
@ast
Safety and efficacy of inflixi ...... ata from the Italian Registry.
@en
type
label
Safety and efficacy of inflixi ...... ata from the Italian Registry.
@ast
Safety and efficacy of inflixi ...... ata from the Italian Registry.
@en
prefLabel
Safety and efficacy of inflixi ...... ata from the Italian Registry.
@ast
Safety and efficacy of inflixi ...... ata from the Italian Registry.
@en
P2093
P921
P356
P1476
Safety and efficacy of inflixi ...... data from the Italian Registry
@en
P2093
Alison Shardlow
Carolina Birolo
Elisabetta Miserocchi
Fabio Vittadello
Fabrizia Corona
Fernanda Falcini
Francesco La Torre
Francesco Zulian
Fulvio Parentin
Giorgia Martini
P356
10.3899/JRHEUM.120583
P407
P577
2012-11-01T00:00:00Z